Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 23;24(1):576.
doi: 10.1186/s12888-024-05961-3.

Impact of moderate-to-high-suicide-intent in major depressive disorder: a retrospective cohort study on patient characteristics and healthcare resource utilisation in England

Tom Denee  1 , Cicely Kerr  2 , Sarah Richards  2 , Natalie Dennis  3 , Astrid Foix-Colonier  3 , Claire Fischer  3 , Fintan Larkin  4
Affiliations

Impact of moderate-to-high-suicide-intent in major depressive disorder: a retrospective cohort study on patient characteristics and healthcare resource utilisation in England

Tom Denee et al. BMC Psychiatry. .

Abstract

Background: Major depressive disorder (MDD) is a disabling mental illness that can affect all aspects of daily life and is a leading cause of healthcare resource utilisation (HCRU).

Aims: We aimed to characterise patients with MDD with moderate-to-high-suicide-intent, compare their HCRU to patients with MDD without moderate-to-high-suicide-intent, and better understand their patient pathways.

Methods: This retrospective cohort study used data collected from primary care electronic health records from Clinical Practice Research Datalink (CPRD), linked to Hospital Episode Statistics, Mental Health Services Data Set, and Office for National Statistics in England. Adults diagnosed with ≥ 1 MDD diagnosis between 04/2007 and 11/2015 were categorised by suicide intent.

Results: 307,476 patients with MDD were included (294,259 patients without moderate-to-high-suicide-intent and 13,217 with moderate-to-high-suicide-intent). Patients with MDD with moderate-to-high-suicide-intent were younger on average (39.0 vs. 44.8 years) and included a lower percentage of females (58% vs. 65%) compared to patients without moderate-to-high-suicide-intent. HCRU was greater among patients with moderate-to-high-suicide-intent than patients without moderate-to-high-suicide-intent during the first follow-up year for general practitioner consultations (38.5 vs. 29.4), psychiatric outpatient visits (1.5 vs. 0.1), psychiatrist visits (3.6 vs. 0.3), emergency visits (1.5 vs. 0.3), and hospitalisations (86% vs. 26%). Overall, 56% of patients with moderate-to-high-suicide-intent had an antidepressant prescription within 30 days from the initial moderate-to-high-suicide-intent.

Conclusions: Patients with MDD and moderate-to-high-suicide-intent were younger, included more males and incurred greater HCRU than those without moderate-to-high-suicide-intent. These results suggest a greater need for effective medical care and appropriate treatments for patients with moderate-to-high-suicide-intent, which could help reduce associated symptoms, mortality, and HCRU.

Keywords: Clinical practice research datalink (CPRD); England; Healthcare Resource use; Hospital episode statistics (HES); Major depressive disorder; Mental health services data set (MHSDS); Office for National statistics (ONS); Population-based study; Suicide intent.

PubMed Disclaimer

Conflict of interest statement

TD, CK, and SR are employees of Janssen, pharmaceutical company of Johnson & Johnson and hold stock options. ND, AFC, and CF are employees of Amaris Consulting. Amaris consulting was contracted by Janssen for the conduct of this study.FL reported honoraria and consulting fees from Janssen and participation in an advisory board for Janssen.

Figures

Fig. 1
Fig. 1
Flow chart for the selection of patients included in the analysis
See this image and copyright information in PMC

References

    1. Greenberg PE, Fournier AA, Sisitsky T, Simes M, Berman R, Koenigsberg SH, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). PharmacoEconomics. 2021;39(6):653–65. 10.1007/s40273-021-01019-4 - DOI - PMC - PubMed
    1. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ. 2006;9(2):87–98. - PubMed
    1. Global regional, Global Burden of Disease Study 2019. and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the. The Lancet Psychiatry [Internet]. 2022 Feb 1 [cited 2022 Aug 22];9(2):137–50. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00395.... - PMC - PubMed
    1. Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet [Internet]. 2021 Nov 6 [cited 2022 Aug 22];398(10312):1700–12. https://www.sciencedirect.com/science/article/pii/S0140673621021437. - PMC - PubMed
    1. de la Torre JA, Vilagut G, Ronaldson A, Serrano-Blanco A, Martín V, Peters M et al. Prevalence and variability of current depressive disorder in 27 European countries: a population-based study. The Lancet Public Health [Internet]. 2021 Oct 1 [cited 2022 Aug 22];6(10):e729–38. https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00047.... - PMC - PubMed

Publication types

LinkOut - more resources